| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS42000227 | EBV | ENSG00000145242.14 | protein_coding | EPHA5 | No | No | 2044 | B7ZKJ3 B7ZKW7 F8VP57 F8W9W0 P54756 |
| TVIS10000126 | HBV | ENSG00000145242.14 | protein_coding | EPHA5 | No | No | 2044 | B7ZKJ3 B7ZKW7 F8VP57 F8W9W0 P54756 |
| TVIS30088802 | HIV | ENSG00000145242.14 | protein_coding | EPHA5 | No | No | 2044 | B7ZKJ3 B7ZKW7 F8VP57 F8W9W0 P54756 |
| TVIS30018050 | HIV | ENSG00000145242.14 | protein_coding | EPHA5 | No | No | 2044 | B7ZKJ3 B7ZKW7 F8VP57 F8W9W0 P54756 |
| TVIS30079126 | HIV | ENSG00000145242.14 | protein_coding | EPHA5 | No | No | 2044 | B7ZKJ3 B7ZKW7 F8VP57 F8W9W0 P54756 |
| TVIS30084578 | HIV | ENSG00000145242.14 | protein_coding | EPHA5 | No | No | 2044 | B7ZKJ3 B7ZKW7 F8VP57 F8W9W0 P54756 |
| TVIS30018679 | HIV | ENSG00000145242.14 | protein_coding | EPHA5 | No | No | 2044 | B7ZKJ3 B7ZKW7 F8VP57 F8W9W0 P54756 |
| TVIS30060097 | HIV | ENSG00000145242.14 | protein_coding | EPHA5 | No | No | 2044 | B7ZKJ3 B7ZKW7 F8VP57 F8W9W0 P54756 |
| TVIS30060098 | HIV | ENSG00000145242.14 | protein_coding | EPHA5 | No | No | 2044 | B7ZKJ3 B7ZKW7 F8VP57 F8W9W0 P54756 |
| TVIS30060099 | HIV | ENSG00000145242.14 | protein_coding | EPHA5 | No | No | 2044 | B7ZKJ3 B7ZKW7 F8VP57 F8W9W0 P54756 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | EPHA5 |
|---|---|
| DrugBank ID | DB01254 |
| Drug Name | Dasatinib |
| Target ID | BE0005587 |
| UniProt ID | P54756 |
| Regulation Type | inhibitor |
| PubMed IDs | 18180381; 29356025 |
| Citations | Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, Lupinek C, Weghofer M, Bennett KL, Herrmann H, Schebesta A, Thomas WR, Vrtala S, Valenta R, Lee FY, Ellmeier W, Superti-Furga G, Valent P: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008 Mar 15;111(6):3097-107. doi: 10.1182/blood-2007-08-104372. Epub 2008 Jan 7.@@Wang X, Zhang M, Ping F, Liu H, Sun J, Wang Y, Shen A, Ding J, Geng M: Identification and Therapeutic Intervention of Coactivated Anaplastic Lymphoma Kinase, Fibroblast Growth Factor Receptor 2, and Ephrin Type-A Receptor 5 Kinases in Hepatocellular Carcinoma. Hepatology. 2019 Feb;69(2):573-586. doi: 10.1002/hep.29792. Epub 2018 Mar 24. |
| Groups | Approved; Investigational |
| Direct Classification | Aromatic anilides |
| SMILES | CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1 |
| Pathways | Dasatinib Inhibition of BCR-ABL |
| PharmGKB | PA162372878 |
| ChEMBL | CHEMBL1421 |
